Positive Breast Cancer Study Boosts Celldex Therapeutics
By Peter Winter
BioWorld Insight Editor
BioWorld Insight Editor
Monday, December 10, 2012
Shares of Celldex Therapeutics Inc. gained 25.5 percent Monday a reaction to the company reporting positive final data on CDX-011 in a Phase II study in metastatic breast cancer.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.